Late diagnosis, modest treatment options and lack of predictive markers of therapy response dictate the poor overall survival (OS) of ~1 year in most gastric cancer (GC) patients. We hypothesized that the level of CD44v6 expression in tumor cells could predict therapy response and prognosis in GC patients.
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Abstract:
Late diagnosis, modest treatment options and lack of predictive markers of therapy response dictate the poor overall survival (OS) of ~1 year in most gastric cancer (GC) patients. We hypothesized that the level of CD44v6 expression in tumor cells could predict therapy response and prognosis in GC patients.
We analyzed a surgical tumor series of GC patients for the extension of CD44v6 membranous immuno-expression, clinical-pathological features, patient survival, and response to therapy. By integrating this information, we assessed the value of CD44v6 expression to predict benefit from current treatment regimens and prognosis in GC patients. We used GC cell lines and mouse xenografts to assess and/validate the biological impact of CD44v6 expression in GC cells behavior.
We demonstrated that GC patients whose tumors present higher levels of CD44v6 membranous expression benefit from adding chemotherapy to surgery as opposed to those without CD44v6 expression. Moreover, patients bearing CD44v6_high tumors presented worse OS than those bearing CD44v6_absent/low tumors, consolidating the role of CD44v6 expression as an independent factor of poor prognosis in this disease. Finally, our in vitro and patients' data pinpoints the CD44v6+ cell population as the driver of tumor recurrence following conventional chemotherapy, in heterogeneous tumors composed by CD44v6-and CD44v6+ cells.
Our study pioneers the identification of CD44v6 as a potential predictive marker of response to conventional chemotherapy, and consolidates CD44v6 as an independent marker of poor prognosis in GC. Overall, our data strongly 4 supports selection of patients with high CD44v6 expressing tumors for conventional chemotherapy with or without surgery, regardless of the TNM stage. 5 
Introduction:
Gastric cancer (GC) is the 3 rd leading cause of cancer related mortality worldwide, with >750,000 deaths estimated to occur every year. 1 Over 70% of GC patients present with locally advanced and/or unresectable disease, for whom conventional chemotherapy (mostly platinum-based) becomes the main treatment option, with a median overall survival (OS) of ~1 year. 2, 3 Despite treatment improvements, the use of targeted therapies in GC has proved disappointing, 4 with the only approved therapies (Trastuzumab, against HER2 and Ramucirumab, against VEGFR2) showing limited OS improvement (2 to 3 months). 5, 6 Therefore, it is crucial to identify biomarkers that can better define prognosis, but mainly that allow predicting who is likely benefitting more from a given treatment regimen. This would trigger better patient stratification for treatment, likely improving OS. CD44, the main hyaluronic acid receptor, is a transmembrane glycoprotein involved in key cellular processes, such as lymphocyte activation, recirculation and homing, as well as epithelial cell adhesion and migration. 7, 8 The human CD44 gene (NG_008937) encodes a polymorphic group of proteins generated by alternative splicing. The standard CD44 isoform (CD44s) includes only the constitutive exons, while the variant isoforms (CD44v) contain one or more variable exons (in addition to the constitutive ones). [7] [8] [9] CD44s is ubiquitously expressed at the surface of most mammalian cells, whereas the expression of CD44v is highly restricted (e.g. during lymphocyte activation and homing) and to specific tissue types. [7] [8] [9] [10] Aberrant expression of CD44v isoforms may occur in diseased cells, and have been associated particularly with several cancerassociated features like invasion and metastization. 9, 11, 12 Moreover, CD44 and 6 its CD44v isoforms are expressed as surface markers of cancer stem cells (CSCs), influencing key CSC-associated properties such as tumor initiation, self-renewal, metastasis and chemoresistance. 9, [13] [14] [15] In the stomach, we have shown that CD44s isoform is widely expressed in both normal and diseased gastric epithelial cells. 16 In contrast, we showed that CD44v6-containing isoforms, which are absent from normal gastric epithelial cells, become overexpressed in stomach premalignant and malignant lesions and display high expression in ~70% of all GCs. 16 Meta-analysis data showed that positive CD44 expression was significantly associated with worse GC patients' prognosis and lower OS, and suggested a similar association for CD44v6 expression. 17 Comparable data exists for other cancer types such as lung, colorectal and breast. 13 Recently, two reports showed a positive association between increased expression of CD44v6 and worse OS in GC patients. 18, 19 However, both studies showed a positive correlation between CD44v6 expression and higher TNM staging, leaving reasonable doubt as to whether CD44v6 tumor expression is an independent factor of poor prognosis in GC. In addition, most articles published on CD44v6 in GC cohorts included a limited number of patients, making it difficult to obtain statistically significant results. No reports exist, exploring whether tumor CD44v6 expression influences patient therapy response. Therefore, we aimed to clarify the role of CD44v6 in GC by using a large GC cohort to investigate, simultaneously, the relationship between CD44v6 expression and clinical-pathological features, patient OS and therapy response. "CD44v6_0" -no staining at the cell membrane; "CD44v6_1+" -membranous staining in less than 10% of tumor cells; "CD44v6_2+" -membranous staining in between 10 and 50% of tumor cells; "CD44v6_3+" -membranous staining in more than 50% of the tumor cells ( Fig 1A) .
Cell lines and culture conditions
Human GC cell lines MKN74 and MKN45 were purchased from the JCRB Cell Bank (Japanese Collection of Research Bioresources Cell Bank), and the noncommercial cell line GP202 cell line was established at Ipatimup. 21 All cell lines were cultured in RPMI 1640 medium with 10% heat inactivated fetal bovine serum (FBS) (Biowest, Nuaillé, France). Cell lines were maintained at 37 ºC and 5% CO2 in a high humidity atmosphere and sub-cultured every 3 to 4 days. Cells were grown in the absence of antibiotics except for cell selection in MKN74 cells, where G418 was used. Cells were never continuously cultured for more than 4 months. Cell identification was confirmed by STR analysis and cells were confirmed to be free of mycoplasma contamination.
Generation of an isogenic cell line model of tumor CD44v6 status
Sequences for CD44s and CD44v6 (a v3-v10 transcript present in GP202) were cloned into a pIRES-EGFP2 plasmid. 22 The conjugates were incubated for 5 min at room temperature and added dropwise to the cells. Upon 48 h of incubation, protein extraction and Western blots were performed to evaluate the efficacy of CD44v6 silencing. In addition, in vitro cisplatin treatments were carried out and apoptosis assessed (as described above). This study is TRIPOD compliant.
Percentage of CD44v6+ cells upon cisplatin incubation

Results:
Consolidation of CD44v6 de novo expression in tumor cells as a poor prognosis marker in GC patients Data on clinical-pathological features and treatment type (Appendix Table 1 ), OS and RFS was collected from a surgical series of 334 GC patients. This series has a good representation of all disease stages and, as expected, patient OS and RFS significantly worsens with increasing pTNM (Pathological Tumor-Node-Metastasis) staging ( Appendix Fig 2A and B) . Analysis of OS and RFS in chemotherapy treated vs. untreated stage II to IV patients, demonstrated that chemotherapy plus surgery increases OS (P < .005), although no advantage was observed for RFS (Appendix Fig 3A and B) .
The extent of CD44v6 membranous expression was analyzed in all cases and tumors were classified into four sub-categories, from absent to high (0, 1+, 2+ and 3+; Fig 1A) : 46% (155/334) were CD44v6_0; 15% (50/334) were CD44v6_1+; 25% (82/334) were CD44v6_2+, and; 14% (47/334) were CD44v6_3+. We found a strong association between high CD44v6 expression and poorer OS ( Fig 1B) . Indeed, GC patients whose tumors express CD44v6 in >50% of tumor cells (CD44v6_3+), have statistically significant worse OS than those lacking CD44v6 expression or if CD44v6 is present in <50% of tumor cells (P < .001) ( Fig 1B) . Therefore, it seemed reasonable to group patients into two expression categories: "CD44v6_absent/low" (combining 0, 1+ and 2+ 13 cases) and "CD44v6_high" (3+ cases). GC patients whose tumors were classified as "CD44v6_high" had significantly worse OS than those with absent/low CD44v6 expression (median OS ~ 15 months vs 51 months, P < .0001; Fig 1C) . When comparing the clinical-pathological features of patients bearing CD44v6_absent/low with those bearing CD44v6_high tumors, we found that CD44v6_high patients more often presented vascular invasion (P < .005), tumor cells in the surgical margins (P < .01) and perineural invasion (P < .05) ( Table 1 ). Multivariate analysis further demonstrated that CD44v6_high was an independent factor of poor prognosis in this series ( Fig 1D) . Additionally, and somehow expected, high pTNM stage (P < .0001), older age at onset (P < .0001) and presence of tumor cells in surgical margins (P = .003) were also identified as independent poor prognosis factors in this series.
In summary, we identified a clear cut-off for defining overexpression of CD44v6 in GC (>50% tumor cells overexpressing membranous CD44v6), which demonstrates prognostic value, likely due to greater ability of CD44v6_high cells to access the vasculature and perineural space, and to spread throughout the stomach wall.
Adding chemotherapy to surgery benefits particularly patients presenting
CD44v6_high tumors
Given that patients bearing "CD44v6_high" tumors present worse prognosis, we hypothesize that they may also respond worse to cisplatin-based therapy.
Indeed, we observed that "CD44v6-high" patients have worse median OS regardless of receiving chemotherapy in addition to surgery or not (Figs 2A and   B ). However, administration of chemotherapy to CD44v6_high patients resulted 14 in a 6-fold increase in their median OS, from 4 to 24 months (Figs 2A and B) .
Although not as striking, the median OS of patients with CD44_absent/low tumors almost doubled (from 20 to 38 months) when treated with conventional chemotherapy in addition to surgery (Figs 2A and B) . This benefit was mainly associated with patients with CD44v6_2+ (Fig 2E) . Overall, these data support chemotherapy not only in CD44v6-high (CD44v6_3+) patients, but also in CD44v6_2+ patients, and fails to support our initial hypothesis that the poor prognosis of CD44v6-high patients is related to weak response to chemotherapy. Indeed, we further verified that the greater the percentage of tumor cells expressing CD44v6, the greater the treatment benefit reflected in the median OS (Figs 2C-G). For instance, CD44v6_1+, 2+ and 3+ patients had Fig 4H) .
These data raise the importance of considering the CD44v6 sub-categorization when selecting patients for chemotherapy, as: (1) chemotherapy significantly improved OS and time to relapse specifically in CD44v6_2+ and 3+ patients, and; (2) chemotherapy does not influence OS and decreases time to relapse in CD44v6 negative (CD44v6_0) patients.
CD44v6 overexpression in GC cell lines influences response to cisplatin treatment
We next wanted to understand how does CD44v6 overexpression influences response to conventional chemotherapeutic agents used in GC treatment, namely cisplatin and 5-fluorouracil . For this, we generated three isogenic GC cell lines: mock cells lacking CD44, CD44s and CD44v6 expressing cells (Appendix Fig 5) .
While no differences were observed between the isogenic cells for doublingtime, invasion, cell-adhesion and motility, tumorigenic potential in vivo (Appendix Fig 6) ; CD44v6 overexpressing cells survived better to cisplatin treatment, by decreasing apoptosis levels ( Fig 3A and C) , but not to 5-FU treatment ( Fig 3B) . To validate these findings, we depleted CD44v6 expression from cells endogenously expressing CD44v6 (Appendix Fig 7) . Indeed, CD44v6 depletion increased cisplatin-induced apoptosis (Fig 3D) , validating our results.
Since some CD44v6 effectors are also implicated in cisplatin resistance, namely STAT3 and P38, we evaluated their modulation in our experimental models.
STAT3 was rapidly activated in CD44v6 overexpressing cells in response to
cisplatin (Appendix Fig 8) . Although this might explain the increased cell survival in CD44v6 overexpressing cells, this behavior was also observed in 16 CD44s cells. This data was not further clarified neither when analyzing P38 expression in the isogenic model nor in cell lines endogenously expressing CD44v6 (data not shown).
Altogether, these in vitro studies clearly and consistently indicated that CD44v6 overexpression increases survival of GC cells in response to cisplatin treatment.
CD44v6 expressing cells may contribute to patient relapse after chemotherapy
We observed that patients' tumors with greater CD44v6+ cell populations relapse faster, following chemotherapy than those with small fractions of this sub-population (Appendix Fig 4H) . In addition, our in vitro results show that CD44v6+ cells survive better than CD44v6-cells in response to cisplatin (included in the chemotherapeutic regimen of most patients studied; Appendix Table 2 ). So, we hypothesized that upon chemotherapy, CD44v6+ cells prevail over the CD44v6-counterpart, triggering faster tumor relapse and dominating recurring lesions. We therefore analyzed the CD44v6 status in surgicallyresected tumors from patients treated with neo-adjuvant chemotherapy or chemo-naïve. Supporting our hypothesis, 50% of tumors treated prior to surgery were CD44v6_3+, comparing to 25% of chemo-naïve tumors (Fig 4A) . Despite the low number of patients, these results suggest that chemotherapy may increase the abundance of CD44v6+ cell population in gastric cancers.
We tested this hypothesis in vitro by incubating co-cultures of CD44v6+ and
CD44v6-cells with cisplatin and subsequently allowing them to recover for 15 days (as an attempt to mimic what happens in patients that receive chemotherapy and then present tumor relapse). We showed that upon recovery, CD44v6+ cells represent >80% of the cell culture, suggesting that CD44v6 is involved in GC cell overgrowth after cisplatin treatment (Figs 4B and C).
Discussion:
Herein, we established a protocol to evaluate CD44v6 in GC, according to the percentage of tumor cells expressing membranous CD44v6. The categorization of CD44v6 expression was further refined through correlation with OS of GC patients, and allowed demonstrating that in GC, CD44v6 is an independent marker of poor prognosis with further potential as a predictive marker of response to conventional chemotherapy. Our data also shed light into GC molecular heterogeneity and its relation with therapy, by suggesting that the CD44v6+ population may be driving recurrence following conventional chemotherapy, in tumors composed of CD44v6+ and CD44v6-cell populations.
Approximately 14% of GC patients present with CD44v6_high tumors (Fig 5A) , which have a significantly worse median OS compared with CD44v6_absent/low patients. Importantly, this occurs independently of TNM staging (Appendix Fig 9A-D) , as demonstrated by multivariate analysis. Studies so far reporting an association between CD44v6 expression and worse GC patient survival, 18, 19 enclosed low patients' number and failed to demonstrate prognostic value for CD44v6 expression independently of TNM staging. Our study addresses this issue in the largest GC patient cohort tested so far, and demonstrates that CD44v6 is truly an independent marker of poor prognosis, as it has been described for colorectal cancer. 25 
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We further demonstrated that CD44v6 expression in tumors predicts benefit from application of conventional chemotherapy in addition to surgery. This benefit is directly proportional to the fraction of CD44v6+ cells in tumors, with patients whose tumors lack CD44v6 expression not benefiting from chemotherapy treatment (Fig 5B-5D ). The latter also appear to have worse RFS and to relapse sooner than CD44v6_0 patients not receiving chemotherapy in addition to surgery. To the best of our knowledge, this is the first report demonstrating CD44v6 as a useful marker to predict therapy response in GC, similarly to what was shown in colorectal cancer, where patients with moderate or strong CD44v6 tumor expression respond better to chemotherapy with irinotecan. 26 Nearly half of the tumors herein studied possess some degree of heterogeneity regarding CD44v6 expression (with CD44v6+ and CD44v6-cell populations coexisting in the same tumor), which may have important consequences in terms of clinical outcome. Our in vitro data shows that CD44v6 expression promotes survival of GC cells after cisplatin treatment, as others have shown for several tumor models, 15, 23, 24 and in co-cultures of CD44v6+ and CD44v6-cells. Our patient data also suggests enrichment in the CD44v6+ cell population after neoadjuvant treatment and in relapses, but validation in larger and/or independent GC patient series is still needed. CD44/CD44v are considered cancer stem cell markers in several tumor types, including GC, 13, 14 supporting our hypothesis that CD44v6+ tumor cells may be potentiating relapse. If our findings are confirmed, strategies to specifically eliminate CD44v6+ cells could lead to decreased recurrence and improved patient survival. One possible strategy is the targeting of CD44v6 downstream effectors, as direct targeting of CD44v6 ought to be avoided due to the lethal skin toxicity side effects described in a Phase I clinical trial using a highly potent antimicrotubule agent coupled to a monoclonal antibody against CD44v6. 27 TNM staging has long been the most important tool to assess prognosis in GC.
Our data shows that evaluating CD44v6 by IHC may provide oncologists with additional and important information for stratifying GC patient for treatment.
Namely, if CD44v6 IHC is performed in GC biopsies and turns out CD44v6_high, this information may be used to recommend surgery combined with chemotherapy. This would be particularly important for patients with CD44v6 2+ or 3+ tumors diagnosed in stage I and stage II, who often do not undergo chemotherapy. Moreover, finding tumors lacking CD44v6 expression could help oncologists selecting patients less likely to benefit from chemotherapy, hence avoiding its related toxicity side effects ( Fig 5E) .
Conclusion
Our study is the first one to identify CD44v6 as a potential predictive marker of response to conventional chemotherapy. In addition, we provide compelling evidence that consolidates CD44v6 is an independent marker of poor prognosis, and a likely marker of faster relapse. Importantly, our data supports selection of patients with high CD44v6 expressing tumors for conventional chemotherapy in addition to surgery, even in TNM stage I and stage II patients, who are generally treated with surgery alone. stratification using CD44v6 as a marker for treatment selection (adapted from 28 ). The obtained data show that patients with operable >T1N0 and CD44v6+ tumors benefit from receiving chemotherapy in addition to surgery. In addition, our data suggests patients with T1N0 and CD44v6+ tumors may benefit from additional chemotherapy, and that patients with inoperable or metastatic GC with CD44v6+ tumors may benefit from more aggressive chemotherapeutic strategies, highlighting the importance of performing additional studies on this issue.
